Clinical Trial Update: Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China

View source ↗

Summary

A real-world study in China is evaluating how Scemblix (asciminib) is used to treat chronic myeloid leukemia in the chronic phase and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• SCEMBLIX (ASCIMINIB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia in Chronic Phase | Status: RECRUITING